Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting Report

The efficacy of Ra-223-dichloride treatment for bone-metastatic lesions in patients with castration-resistant prostatic cancer

Ichiei Kuji, Tomohiko Yamane, Kenji Fukushima, Akira Seto, Nishimoto Koshiro, Tsuyoshi Kaneko, Suguru Shirotake and Masafumi Oyama
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1273;
Ichiei Kuji
1Dept. of Nuclear Medicine Saitama Medical University International Medical Center Hidaka-shi Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomohiko Yamane
1Dept. of Nuclear Medicine Saitama Medical University International Medical Center Hidaka-shi Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenji Fukushima
1Dept. of Nuclear Medicine Saitama Medical University International Medical Center Hidaka-shi Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Seto
1Dept. of Nuclear Medicine Saitama Medical University International Medical Center Hidaka-shi Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nishimoto Koshiro
2Dept. of Uro-Oncology Saitama Medical University International Medical Center Hidaka-shi Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsuyoshi Kaneko
2Dept. of Uro-Oncology Saitama Medical University International Medical Center Hidaka-shi Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suguru Shirotake
2Dept. of Uro-Oncology Saitama Medical University International Medical Center Hidaka-shi Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masafumi Oyama
2Dept. of Uro-Oncology Saitama Medical University International Medical Center Hidaka-shi Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1273

Background: Ra-223-dichloride treatment of castration-resistant prostatic cancer has an alpha radiation-induced radiotherapeutic effect on bone metastases and prolongs the prognosis, but the mechanism by which the prognosis is prolonged is not well understood.

Objectives: The purpose of this study was to observe the changes in bone accumulation using bone scintigraphy during Ra-223-dichloride therapy with a precise single-photon emission computed tomography (CT)/CT (SPECT/CT) device.Subjects and Methods: The subjects were 28 patients with Ra-223-dichloride therapy for castration-resistant prostate cancer bone metastases who provided consent to participate in the study. Using Symbia Intevo (Siemens Healthineers K.K., Japan), a whole-body bone scan, and SPECT/CT were performed before treatment, 1 and 2 months after the initiation of treatment, 1 month after the completion of treatment, and 6 months after the completion of treatment approximately 3 h after the administration of Tc-99m-methyl diphosphonate. For bone scintigraphy, the bone scan index (BSI), maximum standardized uptake value (SUVmax), SUVpeak, SUVmean, metabolic bone volume (MBV), and total bone uptake (TBU) were obtained in the automated analysis application with a cut-off SUV of 12. We also compared blood cell counts and biochemical tests for bone metastases, including white blood cells (WBCs), platelets, hemoglobin, serum prostate-specific antigen (PSA), lactate dehydrogenase, alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BAP), type I collagen cross-linked C-telopeptide (1-CTP), and calcium. Statistical analyses were performed with the Kruskal-Wallis test and post-hoc Dunn's multiple comparisons test. Same analyses were performed for a percent change in each value.

Results: During the course, significant changes were evident in SUVmax (p = 0.026), SUVpeak (p = 0.013), SUVmean (p = 0.0099), and percent changes in SUV, including %SUVmax (p = 0.0004), %SUVpeak (p = 0.0010), and %SUVmean (p = 0.0081), indicating a decrease after the end of treatment compared to the value before the start of treatment. However, there were no significant changes in the index scores reflecting bone metastasis, including BSI (p = 0.88), MBV (p = 0.73), TBU (p = 0.59), %BSI (p = 0.18), %MBV (p = 0.18), and %TBU (p = 0.31). Blood biochemistry revealed significant increases in %PSA (p <0.0001), which is considered to represent the rate of bone metastasis change, 1-CTP (p = 0.02), and %1-CTP (p <0.0001), which represent osteolytic bone metastasis activity. In %ALP (p<0.0001) and %BAP (p = 0.0012), which represent osteogenic activity, a significant decrease was observed during treatment, but it tended to increase after the end of treatment. WBCs (p = 0.094) and platelets (p = 0.50), which reflect the myelosuppressive effect of radiation, did not change significantly while hemoglobin (p = 0.0003) tended to decrease significantly.

Conclusions: Although the elevation of PSA and hemoglobin may lead to the progression of bone marrow lesions during Ra-223-dichloride treatment, elevations of SUVs, ALP, and BAP suggest that areas with a high osteoblastic activity had a high-absorbed dose of alpha radiation and suppressed osteoblastic activity. The amount of bone metastatic lesions demonstrated by BSI, MBV, or TBU did not significantly change, and 1-CTP of osteolytic bone metastases had increased during the treatment. Therefore, the Ra-223-dichloride therapy was considered to have little inhibitory effect on osteolytic metastases and a therapeutic effect mainly on osteoblastic bone metastatic lesions, leading to little effect on the burden of bone metastatic lesions. These results suggest that bone SUVmax may be more useful than BSI in evaluating the efficacy of Ra-233-dichloride therapy.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The efficacy of Ra-223-dichloride treatment for bone-metastatic lesions in patients with castration-resistant prostatic cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The efficacy of Ra-223-dichloride treatment for bone-metastatic lesions in patients with castration-resistant prostatic cancer
Ichiei Kuji, Tomohiko Yamane, Kenji Fukushima, Akira Seto, Nishimoto Koshiro, Tsuyoshi Kaneko, Suguru Shirotake, Masafumi Oyama
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1273;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The efficacy of Ra-223-dichloride treatment for bone-metastatic lesions in patients with castration-resistant prostatic cancer
Ichiei Kuji, Tomohiko Yamane, Kenji Fukushima, Akira Seto, Nishimoto Koshiro, Tsuyoshi Kaneko, Suguru Shirotake, Masafumi Oyama
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1273;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Rest Dose Spillover Correction of Stress Blood Flow Measurements in Digital Rb-82 Myocardial Perfusion PET/CT Imaging
  • Radiolabeled hyaluronic acid (HA) fragments for lymphatic imaging
  • Simplifying and Confirming Ketosis: A Quality Improvement Initiative in Cardiac Sarcoid Assessment
Show more

GU - Radioligand Therapy (Poster Session)

  • The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
  • 99mTc-antigranulocyte scintigraphy for estimation of bone marrow reserve prior to PSMA-radioligand therapy
Show more GU - Radioligand Therapy (Poster Session)

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire